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Abstract
Background: Statin use is associated with a modest increase in the incidence of type 2 diabetes mellitus (DM)
among the general population. However, HIV-infected patients have a higher risk of developing DM, and it is
unclear whether statins have a diabetogenic effect in these patients. Therefore, we investigated the associations of
statin use and exposure to antiretroviral drugs with type 2 DM onset in a cohort of HIV-infected patients.
Methods: This retrospective, controlled, cohort study identified HIV-1-infected patients who did not have DM and
were not receiving statins at their antiretroviral treatment (ART) initiation. Follow-up was accrued from ART initiation
to the earliest instance of a DM diagnosis, loss to follow-up, death, or last available visit. The incidence of DM was
estimated according to statin use, which was adjusted for periods without statin treatment. The Fine-Gray
competing risk model was used in the multivariate analysis to identify risk factors for developing DM.
Results: The analyses evaluated 6,195 patients followed for 9.8 years (interquartile range: 4.3–16.3 years). During
64,149 person-years of follow-up (PYFU), 235 patients developed DM (crude incidence: 3.66 [95%CI: 3.20–4.13] per
1,000 PYFU), and 917 (14%) patients used statins. After adjusting for potential confounders, statin use was
associated with a non-significant increase in the risk of DM (AHR: 1.21, 95% CI: 0.71–2.07; P = 0.47). DM was more
likely among patients who were ever treated with stavudine, and less likely among those ever treated using
emtricitabine, tenofovir, abacavir, efavirenz, nevirapine, atazanavir or darunavir.
Conclusions: A higher risk of diabetes mellitus was not associated with statin treatment but with traditional risk
factors and stavudine use while a reduced risk of DM was associated with the use of emtricitabine, tenofovir,
abacavir, efavirenz, nevirapine, atazanavir or darunavir.
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Background
Hypercholesterolemia is common among HIV-infected
patients who are receiving antiretroviral therapy (ART) [1]
and can contribute to the increased risk of cardiovascular
disease in this population [2, 3]. Therefore, 3-hydroxy-3-
methylglutaryl-coenzymeA (HMG-CoA) reductase inhibi-
tors (statins) are recommended [4] and extensively
prescribed to treat hypercholesterolemia and to prevent
cardiovascular events among HIV-infected patients. In
additional to their cholesterol-lowering properties, statins
have recently been associated with reductions in overall
mortality [5–7], the risk of non-AIDS malignancies [7, 8]
and the risk of AIDS-defining malignancies [8, 9] among
HIV-infected patients.
In contrast, concerns have recently been raised re-
garding glucose metabolism impairment among statin
users, with different studies in the general population
revealing a possible association between statin use
and the risk of incident type 2 diabetes mellitus (DM)
[10, 11], as well as a dose-related effect [12]. Al-
though the mechanisms underlying this increased risk
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of incident DM are not fully understood, Mendelian
randomization studies [13] suggest that they are re-
lated, at least in part, to reduced HMG-CoA reduc-
tase activity [14]. Therefore, the possible diabetogenic
effect of statins may be particularly relevant among HIV-
positive patients, who have a higher risk of developing
DM, compared to the general population [15].
Unfortunately, there are few studies regarding statin
use and incident DM among HIV-infected patients, and
these studies have reported not univocal results. For ex-
ample, a randomized study [16] of 72 patients reported
that rosuvastatin use was associated with increased insu-
lin resistance but not with a clinical diagnosis of DM
and a recent italian study did not observe any associ-
ation between statins use and DM risk [17]. In contrast,
the HOPS cohort study [18] found a slightly increased
risk of incident DM among patients who were treated
using statins. Therefore, the present study aimed to
evaluate the associations of statin use and exposure to
antiretroviral drugs with the onset of type 2 DM in a
large cohort of HIV-infected patients.
Methods
This retrospective observational study was approved by
the ethics committee of the San Raffaele Scientific Insti-
tute, and examined patient data from the Infectious Dis-
eases Department database at the San Raffaele Hospital
(IDD-HSR). This observational database collects demo-
graphic, clinical, therapeutic, and laboratory data from
adult patients who are receiving primary inpatient or
outpatient care for HIV infection at the Infectious Dis-
eases Department of the San Raffaele Scientific Institute
(Milan, Italy). At their first visit to the clinic, the patients
provide written informed consent for scientific analysis
of their clinical and laboratory data. Information regard-
ing the prescribed antiretroviral and concomitant drugs
(type, dosage, and dates of start and stop) are prospect-
ively recorded at each visit by the treating physician, and
these data are subsequently checked by skilled data man-
agers. However, patient adherence to the prescribed
drugs is not routinely assessed.
In the present study, we included adults who were in-
fected with HIV-1 and subsequently started ART be-
tween January 1991 and November 2014. These patients
were not using statins, had not been diagnosed with type
2 DM at the start of ART, and had undergone at least
one test to determine their fasting glucose and lipid
levels after starting the ART (i.e., one follow-up examin-
ation in addition to that of baseline). Details of the pa-
tients’ selection process is illustrated in the Additional
file 1: Figure S1.
We diagnosed DM according to the American Dia-
betes Association criteria [19], based on two consecutive
fasting plasma glucose levels of ≥126 mg/dL, or a 2-h
plasma glucose level ≥200 mg/dL during an oral glucose
tolerance test, or two consecutive fasting glycated
hemoglobin levels of ≥48 mmol/mol, or a prescription
for any antidiabetic medication [the median (IQR) num-
ber of fasting glucose determinations per patient was 29
(13–50)]. An expert physician (VS) and a diabetologist
(PP) reviewed all diagnoses to verify the data’s plausibil-
ity and completeness before the analyses. We excluded
patients with a diagnosis of type 2 DM before the initi-
ation of ART (prevalent cases).
In the present study, all statin treatments were started
after the initiation of ART, and preceded the diagnosis of
DM (if applicable). Patients were required to receive a
statin for at least 30 days to be considered a statin user.
To evaluate the effect of statin dose on the incidence of
DM, we considered the following dose categories [11]:
high dose (rosuvastatin at ≥40 mg or atorvastatin at
≥80 mg), moderate dose (rosuvastatin at 10–40 mg,
atorvastatin at 20–80 mg, or simvastatin at ≥80 mg), and
low dose (rosuvastatin at <10 mg, atorvastatin at
<20 mg, simvastatin at <80 mg, or fluvastatin and prava-
statin at any dose); patients were categorized according
to the highest dose category recorded during follow-up.
Follow-up was counted from the date of starting ART
(baseline) to the earliest instance of a type 2 DM diagno-
sis, death, loss to follow-up, or last available visit.
Results were reported as median (interquartile range
[IQR]) or frequency (%), as appropriate. The baseline
characteristics of HIV-infected patients according to sta-
tin use were compared using the chi-square test for cat-
egorical variables and the Wilcoxon rank-sum test for
continuous variables. Crude rates of incident type 2 DM
were reported as events per 1,000 person-years with the
exact 95% Poisson confidence intervals (CIs) among the
entire sample, non-statin users, and statin users (the cal-
culation for statin users accounted for their periods of
non-use) [20].
The effect of death as an event competing with the on-
set of type 2 DM was modeled using the Fine-Gray
model [21], and factors that were associated with the on-
set of type 2 DM were identified using subhazard ratios
(a measure of relative risk that considers death). No
major violations of the proportional-hazards assumption
were detected using the interactions terms of the predic-
tors as a function of time. The multivariate model
(Model 1) included characteristics with a p-value of ≤ .20
in the univariate analyses or factors that are commonly
associated with DM (e.g., smoking or hepatitis C virus
[HCV] co-infection) in addition to the calendar year of
ART initiation. We classified patients as smokers if they
had smoked at least once, and patients who were anti-
HCV-positive based on at least one positive HCV-
antibody test result. Patients were categorized according
to the highest BMI recorded during the follow-up. Race
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was not included in the multivariate models, as almost
all patients (with or without DM) were white. All ART
drugs that were used by at least 25% of the patients and
darunavir (used by 23%) were also included in the multi-
variate models (regardless of their p-value in the
univariate analyses) to investigate the association be-
tween these drugs and DM occurrence. The use of rito-
navir included both full and boosting doses. Statin use
was considered as a time-updated variable: patients who
had a history of statin prescriptions during the follow-up
Table 1 Patients characteristics according to occurrence of type 2 diabetes
Characteristics Type 2 diabetes (n = 235) No type 2 diabetes (n = 5960) p-value
Age (years), median (IQR) 40.3 (35.6–50.0) 35.3 (30.2–41.6) <0.001a
Males, n (%) 201 (86%) 4627 (78%) 0.002b
White Race, n (%) 224 (95%) 5542 (93%) 0.16b
Smoke, n (%) 0.96b
Current/ex-smoker 99 (42%) 2384 (40%)
Never 75 (32%) 2086 (35%)
Unknown 61 (26%) 1490 (25%)
Body Mass Index, n (%) <0.001b
Normal (<25 kg/m2) 83 (35%) 2463 (41%)
Overweight (25–29.9 kg/m2) 69 (29%) 1425 (24%)
Obese (≥30 kg/m2) 34 (15%) 355 (6%)
Unknown 49 (21%) 1717 (29%)
HIV risk factor, n (%) 0.015b
IVDU 46 (20%) 1134 (19%)
MSM 54 (23%) 1893 (32%)
Heterosexual 49 (21%) 1225 (21%)
Other/Unknown 86 (37%) 1708 (29%)
Ab-anti HCV, n (%) 0.014b
Positive 83 (35%) 1617 (27%)
Negative 135 (58%) 3729 (63%)
Unknown 17 (7%) 613 (10%)
HBsAg, n (%) 0.004b
Positive 21 (9%) 323 (5%)
Negative 197 (84%) 4853 (82%)
Unknown 17 (7%) 784 (13%)
Years since first HIV-positive test, median (IQR) 19.0 (14.4–25.6) 14.4 (7.7–20.9) <0.001a
AIDS diagnosis before ART, median (IQR) 29 (12%) 599 (10%) 0.27b
Nadir CD4 cell count before ART (cells/μL), median (IQR) 231 (91–395) 285 (165–408) 0.019a
Baseline Total Cholesterol (mg/dL), median (IQR) 153 (127–198) (available in 126 pts) 157 (132–183) (available in 2271 pts) 0.92a
Baseline HDL-cholesterol (mg/dL), median (IQR) 35 (31–40) (available in 6 pts) 38 (32–45) (available in 1056 pts) 0.53a
Baseline LDL-cholesterol (mg/dL), median (IQR) 98 (84–114) (available in 4 pts) 100 (80–121) (available in 985 pts) 0.87a
Baseline Fasting Glucose (mg/dL), median (IQR) 96 (85–106) (available in 51 pts) 85 (79–92) (available in 2626 pts) <0.001a
Baseline Triglycerides (mg/dL), c 144 (116–206) (available in 43 pts) 103 (75–150) (available in 2324 pts) <0.001a
Baseline CD4 cell count (cells/μL), median (IQR) 240 (99–422) (available in 126 pts) 307 (177–443) (available in 3557 pts) 0.018a
Baseline HIV-RNA (log10 copies/ml), median (IQR) 4.78 (4.17–5.31) (available in 76 pts) 4.74 (4.16–5.20) (available in 2929 pts) 0.65
a
Baseline haemoglobin (mg/dl), median (IQR) 13.7 (11.9–15.1) (available in 61 pts) 14.0 (12.7–14.9) (available in 2883 pts) 0.63a
Baseline creatinine (mg/dl), median (IQR) 0.87 (0.72–0.96) (available in 34 pts) 0.82 (0.71–0.93) (available in 2205 pts) 0.70a
Baseline: date of ART initiation; if not indicated the characteristic is intended at the censoring date
a by Wilcoxon rank sum test
b by Chi-square or Fisher exact test, as appropriate
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were alternatively considered over time as either non-
statin users or statin users depending on whether they
were receiving the treatment or not. The other time-
updated covariates were age, CD4+, HIV RNA,
hemoglobin levels, and fasting levels of glucose and
triglycerides. A second multivariate model accounted for
the effect of an additional risk factor (Model 2) including
high-density lipoprotein (HDL)-cholesterol (time-up-
dated variable), as this factor is independently associated
with new-onset DM [22].
Table 2 Patients characteristics according to statins use
Characteristics Statin users (n = 917) Non-Statin users (n = 5278) p-value
Age (years), median (IQR) 38.6 (32.3–45.9) 35.1 (30.2–41.1) <0.001a
Males, n (%) 722 (79%) 4106 (78%) 0.55b
White Race, n (%) 881 (96%) 4909 (93%) 0.09 b
Smoke, n (%) <0.001 b
Current/ex-smoker 395 (43%) 2088 (39%)
Never 271 (30%) 1870 (38%)
Unknown 251 (27%) 1320 (23%)
Body Mass Index, n (%) <0.001 b
Normal (<25 kg/m2) 409 (45%) 2137 (41%)
Overweight (25–29.9 kg/m2) 323 (35%) 1171 (22%)
Obese (≥30 kg/m2) 100 (11%) 289 (5%)
Unknown 85 (9%) 1681 (32%)
HIV risk factor, n (%) <0.001 b
IVDU 73 (8%) 1107 (21%)
MSM 246 (27%) 1028 (20%)
Heterosexual 352 (38%) 1595 (30%)
Other/Unknown 246 (27%) 1548 (29%)
Ab-anti HCV, n (%) <0.001 b
Positive 136 (15%) 1564 (30%)
Negative 721 (77%) 3143 (60%)
Unknown 60 (7%) 570 (11%)
HBsAg, n (%) 0.001 b
Positive 42 (5%) 302 (6%)
Negative 787 (86%) 4263 (81%)
Unknown 88 (10%) 713 (14%)
Years since first HIV-positive test, median (IQR) 18.0 (11.5–22.8) 14.1 (7.4–20.7) <0.001a
AIDS diagnosis before ART, median (IQR) 96 (11%) 532 (10%) 0.72 b
Nadir CD4 cell count before ART (cells/μL), median (IQR) 285 (177–398) 283 (160–412) 0.99a
Baseline Total Cholesterol (mg/dL), median(IQR) 183 (154–207) (available in 301 pts) 154 (131–179) (available in 2013 pts) <0.001 a
Baseline HDL-cholesterol (mg/dL), median(IQR) 38 (32–44) (available in 123 pts) 38 (32–45) (available in 939 pts) 0.56 a
Baseline LDL-cholesterol (mg/dL), median (IQR) 124 (102–150) (available in 111 pts) 98 (79–117) (available in 878 pts) <0.001 a
Baseline Fasting Glucose (mg/dL), median (IQR) 88 (81–95) (available in 375 pts) 85 (79–92) (available in 2302 pts) <0.001 a
Baseline Triglycerides (mg/dL), median (IQR) 110 (82–170) (available in 318 pts) 102 (75–148) (available in 2049 pts) <0.001 a
Baseline CD4 cell count (cells/μL), median (IQR) 300 (186–433) (available in 564 pts) 307 (171–444) (available in 3119 pts) 0.75 a
Baseline HIV-RNA (log10 copies/ml), median(IQR) 4.72 (4.18–5.15) (available in 421 pts) 4.74 (4.15–5.20) (available in 2584 pts) 0.85
a
Baseline hemoglobin (mg/dl), median (IQR) 13.9 (12.8–14.8) (available in 403 pts) 14 (12.7–14.9) (available in 2541 pts) 0.72 a
Baseline creatinine (mg/dl), median (IQR) 0.85 (0.75–0.95) (available in 287 pts) 0.81 (0.71–0.93) (available in 1952 pts) 0.017 a
Baseline: date of ART initiation; if not indicated the characteristic is intended at the censoring date
a by Wilcoxon rank sum test
b by Chi-square or Fisher exact test, as appropriate
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All statistical tests were two-sided at the 5% level and
were performed using SAS software (version 9.2; SAS
Institute, Cary, NC).
Results
We evaluated data from 6,195 patients, who included
4,828 (78%) men. The median age at the end of follow-
up was 47.2 years (IQR: 40.6–52.7 years), the median
time since the first HIV-positive result was 15 years
(IQR: 8–21 years), and the median duration of ART was
10 years (IQR: 4–16 years). Approximately 27% of the
patients exhibited HCV-positive serology results, 6% of
the patients had a reactive HBV surface antigen. The
median nadir CD4+ cell count was 283 cells/μL (IQR:
162–408 cells/μL), 10% of the patients were diagnosed
with AIDS before initiating ART, 28% of the patients
were smokers, and the median BMI was 23.0 kg/m2
(IQR: 21.1–25.7 kg/m2). The median baseline laboratory
results were total cholesterol levels of 157 mg/dL (IQR:
132–184 mg/dL), low-density lipoprotein (LDL) choles-
terol levels of 100 mg/dL (IQR: 80–121 mg/dL), HDL-
cholesterol levels of 38 mg/dL (IQR: 32–45 mg/dL), tri-
glyceride levels of 104 mg/dL (IQR: 75–152 mg/dL),
fasting plasma glucose levels of 85 mg/dL (IQR: 79–
92 mg/dL), CD4+ cell counts of 307 cells/μL (IQR: 174–
442 cells/μL), and log10 HIV RNA levels of 4.74 (IQR:
4.16–5.20). During the follow-up, 97% of the patients
used nucleoside reverse transcriptase inhibitors (NRTIs),
79% of the patients used protease inhibitors (PIs), 61%
of the patients used non-nucleoside reverse transcriptase
inhibitors, 12% of the patients used integrase strand
transfer inhibitors, and 9% of the patients used entry
inhibitors.
During 64,149 person-years of follow-up, 235 patients
developed DM, which corresponded to a crude inci-
dence rate of 3.66 per 1,000 person-years of follow-up
(95% CI: 3.20–4.13 per 1,000 person-years of follow-up).
The patients’ characteristics according to DM status are
reported in Table 1. Patients with new-onset DM were
more likely to be older, male, overweight or obese, co-
infected with HCV or HBV, exhibit prolonged HIV in-
fection, and have a lower CD4+ cell count nadir. When
we analyzed the exposures to ART drugs according to
the occurrence of DM (Additional file 2: Table S1), we
observed that patients with DM were more likely to be
exposed to “first-generation” NRTIs (e.g., zidovudine,
stavudine, didanosine and lamivudine) or PIs (indinavir,
nelfinavir, and saquinavir), compared to patients without
DM.
In total, 917 patients used statins during the follow-up,
and their characteristics are listed in Table 2. We ob-
served a significant difference in the risk factors for car-
diovascular disease between statin users and non-users,
and statin users also exhibited higher baseline glucose
levels, a longer duration of HIV infection and a longer
duration of ART. The median calendar year of statin ini-
tiation was 2011 (2009–2012) and the median duration
of statin therapy was 37.3 months (IQR: 20.3–
59.2 months), which accounted for 25% of the total
follow-up among the statin users. The most commonly
prescribed statins were rosuvastatin (n = 766, 83.5%) and
atorvastatin (n = 95, 10.4%).
The incidence of DM according to statin use is re-
ported in Table 3. Patients who developed DM exhibited
a similar duration of statin treatment, compared to pa-
tients who did not develop DM (37.7 months [IQR:
20.3–60.1 months] vs. 32.7 months [IQR: 14.8–
44.2 months], respectively; P = 0.13). High-dose statin
therapy was used by 2/23 (8.7%) of the patients who de-
veloped DM, compared to by 21/894 (2.3%) of the pa-
tients who did not developed DM (P = 0.11).
The results from the univariate analyses of DM risk by
use of the Fine-Gray models are reported in Table 4.
In the multivariate analysis (Model 1, Table 5), we ob-
served that a lower risk of DM was associated with
higher values of CD4+ cell count and exposure to abaca-
vir, emtricitabine, tenofovir, efavirenz, nevirapine, ataza-
navir, darunavir. In contrast, a higher risk of DM was
associated with the use of stavudine, older age, obesity,
detectable HIV RNA levels, higher current triglyceride
levels, higher current fasting glucose levels, higher
current hemoglobin levels and shorter ART duration.
Statin use was associated with a non-significant increase
in the risk of DM (adjusted hazard ratio [AHR] 1.21,
95% CI: 0.71–2.07; P = 0.47). The statin-dependent risk
of developing DM was not significantly affected by the
Table 3 Incidence of type 2 diabetes according to statin use
Characteristic Statins users (n = 917) Non-Statin users (n = 5278) p-value
Diagnoses of type 2 diabetes 23 (2.5%) 212 (4.0%) 0.025a
Person-years of follow-up (PYFU)
median follow-up (IQR), years
12720 15.4 (8.9–18.1) 51429 8.9 (3.8–15.5) <0.001b
Incidence rate of type 2 diabetes (95%CI) per 1000-PYFU 7.1 (4.2–10.1) c 3.5 (3.0–4.0) 0.041d
a by Chi-square test
b by Wilcoxon rank-sum test
c Incidence rate of statin users was calculated using only PYFU effectively spent on statin treatment while their untreated PYFU was added to PYFU of
non-statin users
d by univariate Fine-Gray regression model [HR = 1.58 (95%CI: 1.02–2.46)]
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Table 4 Univariate analyses on the risk for DM occurrence by Fine and Gray regression models
Characteristics HR 95% CI p-value
Age (per 5-years higher) a 1.477 1.406–1.551 <0.001
Gender (male vs female) 2.037 1.400–2.963 <0.001
Smoking 0.28
Current/ex-smoker vs never 0.764 0.545–1.070 0.12
unknown vs never 0.904 0.572–1.429 0.67
BMI <0.001
≥25 < 30 vs <25 kg/m2 1.401 1.001–1.959 0.049
>30 vs <25 kg/m2 2.706 1.768–4.143 <0.001
Unknown vs < 25 kg/m2 1.574 1.085–2.282 0.017
HIV risk factor <0.001
IVDU vs heterosexual 0.785 0.515–1.197 0.26
MSM vs heterosexual 0.932 0.622–1.396 0.73
Other/unknown vs heterosexual 1.646 1.138–2.380 0.008
Ab-anti HCV 0.55
Positive vs negative 0.991 0.744–1.320 0.95
Unknown vs negative 1.350 0.775–2.351 0.29
HbsAg 0.14
Positive vs negative 1.608 0.998–2.593 0.051
Unknown vs negative 1.169 0.683–2.003 0.57
Years since first HIV positive test (per 5-years longer) 0.847 0.759–0.946 0.003
Nadir CD4+ cell count before ART (per 100-cells/μL higher) 0.889 0.803–0.984 0.023
AIDS diagnosis before ART (yes vs no) 1.273 0.841–1.929 0.25
Current CD4+ (per 100-cells/μL higher) a 0.950 0.893–1.010 0.10
Current HIV-RNA (per log10 copies/ml) a 1.261 1.113–1.428 <0.001
Current HIV-RNA a
≥50 vs <50 copies/ml 1.521 1.101–2.101 0.011
Current total cholesterol (per 50-mg/dL higher) a 1.027 0.834–1.265 0.80
Current HDL-cholesterol (per 5-mg/dL higher) a 0.906 0.822–0.999 0.047
Current LDL-cholesterol (per 10-mg/dL higher) a 1.031 0.951–1.117 0.46
Current triglycerides (per 50-mg/dL higher) a 1.061 1.047–1.076 <0.001
Current haemoglobin (per 5-g/dl higher) a 1.746 1.020–2.988 0.042
Current fasting glucose (per 10-mg/dL higher) a 1.159 1.136–1.184 <0.001
Current HOMA-IR (per 1-unit higher) a 1.059 1.038–1.080 <0.001
Current FIB-4 (per 0.5-unit higher) a 1.003 1.001–1.006 0.02
Current Framingham 10-year CVD risk (per 5% higher) a 1.188 1.117–1.263 <0.001
Use of statins (yes vs no) a 1.583 1.019–2.457 0.041
Calendar year of ART start (per 3-years increase) 1.133 1.047–1.227 0.002
Ever use of lamivudine (yes vs no) 0.374 0.254–0.550 <0.001
Ever use of abacavir (yes vs no) 0.516 0.393–0.677 <0.001
Ever use of emtricitabine (yes vs no) 0.163 0.119–0.225 <0.001
Ever use of tenofovir (yes vs no) 0.148 0.112–0.195 <0.001
Ever use of stavudine (yes vs no) 0.631 0.482–0.827 0.001
Ever use of zidovudine (yes vs no) 0.834 0.594–1.172 0.30
Ever use of didanosine (yes vs no) 0.453 0.345–0.595 <0.001
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additional inclusion of HDL-cholesterol levels (Model 2,
AHR 1.58, 95% CI: 0.90–2.78; P = 0.11).
Discussion
In the present study, we found that statin use was asso-
ciated with a non-significant increase in the risk of DM
occurrence among HIV-infected patients who were re-
ceiving ART. Furthermore, this increased risk became
statistically significant when we considered the use of
only high-dose statins. In this context, other studies have
reported a dose-related diabetogenic effect for statins in
the general population [12] which is probably associated
to the degree of inhibition of HMG-CoA reductase ac-
tivity [13]. However, there are no clear data regarding
the association between statin use and DM occurrence
among HIV-infected patients. For example, recent
results from the randomized SATURN-HIV trial [16] re-
vealed that the use of rosuvastatin (10 mg daily for
96 weeks) was associated with increased insulin resist-
ance and poorer homeostatic model assessment of insu-
lin resistance outcomes, but not with a clinical diagnosis
of DM, among 72 HIV-infected patients. In line with our
findings, the study by Calza et al. [17] evaluated a cohort
of 3170 HIV-positive patients with a median follow-up
of 5.2 years and concluded that statin use was not asso-
ciated with the occurrence of DM [hazard ratio of 1.09
per year of statin exposure (95% confidence interval 0.7–
1.49; P = 0.067)]. In contrast, a study of the HOPS co-
hort [18] reported a 14% increase in the incidence of
DM for each year of statin use, although the authors did
not specifically analyze the association between statin
dose and DM occurrence. However, as the cardiovascu-
lar benefits of high-dose statin use outweigh the poten-
tial risk of developing DM [23], it may be advisable to
regularly monitor for changes blood glucose and gly-
cated hemoglobin levels in patients who are receiving
high-dose statins and have a high risk of developing
DM.
In the present study, DM occurrence was also related to
classic risk factors for type 2 DM among HIV-infected pa-
tients, such as older age, obesity, higher plasma levels of
triglycerides and glucose [15, 22, 24–26], and HCV
co-infection [27, 28]. Moreover, we found that stavu-
dine use was associated with DM occurrence. In this
context, the deleterious effects of stavudine on glu-
cose metabolism have already been described, [22, 29]
and these effects appear to be secondary to mito-
chondrial toxicity and the occurrence of lipoatrophy,
which are both related to DM occurrence [30, 31].
Interestingly we observed that a reduced risk of
DM was associated with the use of abacavir, emtrici-
tabine, tenofovir, efavirenz, nevirapine, atazanavir and
darunavir. Previous studies have reported, albeit not
consistently, that treatment using first-generation
NRTIs or PIs may increase the risk of DM occurrence
[22, 24–26, 29, 32], although there are very little data
regarding the effect of more recently approved ART
drugs on glucose metabolism. Nevertheless, the drugs
that were associated with a reduced risk of DM in
the present study are not clearly associated with
ART-related risk factors for DM, such as severe mito-
chondrial toxicity, lipoatrophy, or lipodystrophy.
Therefore, it is possible that these drugs had a rela-
tively limited effect on glucose metabolism, compared
to first-generation PIs and NRTIs [33–38].
The present study included several limitations that
warrant consideration. First, the retrospective design
limited the control over the previously collected data
and doesn’t exclude that some residual confounding may
still exists although we are confident that the major con-
founders were considered. Second, the assessment of the
potential relationship between statin dose and incident
DM provide limited evidence of this association given
the limited number of patients and, for this reason, this
analysis is to be intended as exploratory.
Third, it is possible that we have overestimated the ef-
fect of statins on DM occurrence, as we considered pa-
tients as statin users based on their treatment history
alone, and did not consider any possibility of non-
compliance with treatment. Finally, we did not have suf-
ficient statistical power to examine the effect of different
type of statins on incident DM.
Nevertheless, the present study also included several
important strengths. First, we followed-up patients on a
Table 4 Univariate analyses on the risk for DM occurrence by Fine and Gray regression models (Continued)
Ever use of efavirenz (yes vs no) 0.523 0.394–0.695 <0.001
Ever use of nevirapine (yes vs no) 0.440 0.325–0.597 <0.001
Ever use of ritonavir (yes vs no) 0.309 0.227–0.420 <0.001
Ever use of saquinavir (yes vs no) 0.586 0.442–0.777 <0.001
Ever use of lopinavir (yes vs no) 0.322 0.236–0.439 <0.001
Ever use of atazanavir (yes vs no) 0.275 0.201–0.376 <0.001
Ever use of darunavir (yes vs no) 0.182 0.110–0.301 <0.001
Abbreviations: HR, hazard ratio; 95%CI, 95% confidence interval of the hazard ratio; NE, not evaluated due to the limited number of patients treated with this drug
aTime-updated covariate
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regular basis (glucose testing at least twice per year),
which eliminates the possibility that we underestimated
the incidence of DM. Second, our DM diagnoses were
accurate, as each case was individually reviewed and
confirmed to fulfil the American Diabetes Association
criteria. Third, we included a large cohort of HIV-
infected patients who had available data from a relatively
long follow-up.
Table 5 Multivariate analysis on the risk for DM occurrence by Fine and Gray regression model (model 1; the model included 186
DM diagnoses)
Characteristics AHR 95% CI p-value
Age (per 5-years older) 1.36 1.26–1.46 <0.0001
Gender (male vs female) 1.08 0.66–1.76 0.771
Smoking
Current/ex-smoker vs never 1.16 0.79–1.71 0.439
Unknown vs never 0.48 0.24–0.98 0.044
BMI
≥25 < 30 vs <25 kg/m2 1.07 0.71–1.60 0.761
>30 vs <25 kg/m2 2.43 1.34–4.40 0.003
unknown vs < 25 kg/m2 1.02 0.57–1.82 0.954
HIV risk factor
IVDU vs heterosexual 0.58 0.29–1.16 0.125
MSM vs heterosexual 0.96 0.56–1.63 0.877
Other/unknown vs heterosexual 1.18 0.70–1.99 0.536
Ab-anti HCV
Positive vs negative 1.50 0.91–2.48 0.113
Unknown vs negative 0.71 0.31–1.61 0.413
Calendar year of ART initiation (per 3-years longer) 1.30 1.14–1.49 <0.0001
CD4+ (per 100-cells/μL higher) a 0.91 0.84–0.99 0.025
HIV-RNA a
≥50 vs <50 copies/ml 2.00 1.41–2.84 0.0001
Triglycerides (per 50-mg/dl) a 1.07 1.05–1.09 <0.0001
Haemoglobin (per 5-g/dl higher) a 2.59 1.47–4.55 0.001
Fasting glucose (per 10-mg/dL higher) a 1.17 1.15–1.20 <0.0001
Use of statins (yes vs no) a 1.21 0.71–2.07 0.474
Ever use of lamivudine (yes vs no) 0.71 0.36–1.40 0.325
Ever use of abacavir (yes vs no) 0.53 0.36–0.77 0.0008
Ever use of emtricitabine (yes vs no) 0.30 0.17–0.54 <0.0001
Ever use of tenofovir (yes vs no) 0.48 0.29–0.81 0.006
Ever use of stavudine (yes vs no) 1.58 1.02–2.44 0.042
Ever use of zidovudine (yes vs no) 1.62 0.97–2.70 0.067
Ever use of didanosine (yes vs no) 0.98 0.66–1.46 0.932
Ever use of efavirenz (yes vs no) 0.66 0.45–0.97 0.034
Ever use of nevirapine (yes vs no) 0.36 0.23–0.56 <0.0001
Ever use of ritonavir (yes vs no) 0.95 0.60–1.53 0.845
Ever use of saquinavir (yes vs no) 0.91 0.60–1.38 0.643
Ever use of lopinavir (yes vs no) 0.76 0.38–1.02 0.064
Ever use of atazanavir (yes vs no) 0.44 0.29–0.65 <0.0001
Ever use of darunavir (yes vs no) 0.24 0.13–0.45 <0.0001
Abbreviations: AHR adjusted hazard ratio, 95%CI, 95% confidence interval of the hazard ratio
aTime-updated covariate
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Conclusions
In conclusion, a higher risk of DM was not associated
with the use of statin but with previous use of stavudine,
shorter ART duration, detectable HIV RNA levels,
hypertriglyceridemia, hyperglycemia, higher hemoglobin
levels, older age and obesity. In contrast, a lower risk of
developing DM was associated with higher CD4+ cell
counts and the use of emtricitabine, tenofovir, efavirenz,
nevirapine, atazanavir and darunavir.
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